1 · MARCH 2025
FDA approves VYKAT XR for hyperphagia, ages 4 and up. First drug ever on this indication. The label already carries a fluid-overload warning, from edema seen in trials.
SAFETY SIGNAL · 2026
Seven deaths reported after Vykat XR launch. Patient groups responded. Here is what they actually said.
Vykat XR (diazoxide choline) became the first FDA-approved hyperphagia drug in March 2025. By 31 July 2026 the FDA adverse-event system held reports of seven deaths and more than 100 serious events in people who had taken it. On 12 August, three PWS patient organizations issued a joint statement. It did not say stop the drug. It said: select patients more carefully and monitor more.
THE TIMELINE
March 2025 to August 2026, in five beats
One approval, one withdrawal study, one accumulating signal, one letter, one halted rival.
WHAT THE STATEMENT ACTUALLY SAYS
Read the letter before the headlines
The clinician statement, backed by FPWR, IPWSO and PWSA|USA, is unusually careful for a crisis document. It opens by stating the purpose flatly: to increase awareness of the risks for people with PWS when starting Vykat XR. It lists the numbers, then immediately does the thing headlines skipped: it puts them in context. People with PWS already die at one to three percent per year across all ages, from the syndrome itself, especially when weight and sleep apnea are not controlled. The reported cases involved complex medical issues, multiple medications, and pre-existing obesity. It cannot be determined from these reports, the clinicians write, whether the deaths are directly related to the drug or part of the underlying challenges of PWS.
Then it does the constructive part. Risk factors that deserve study before the drug is started: severe obesity, underlying heart disease, pre-existing edema, severe breathing issues including hypoventilation, untreated sleep apnea, and a history of severe respiratory infections. For prescribers: individual assessment, slower titration, an echocardiogram or fluid assessment before and during treatment for higher-risk patients, and a reminder of a PWS-specific trap, that individuals with PWS often do not complain of pain or discomfort. One more PWS-specific detail sits in the risk list: a high pain threshold and reduced illness signaling mean swelling can be far along before anyone notices.
The statement closes by pointing to a recent physician-authored publication with practical guidance on patient selection and monitoring (PMID 42100354), and by welcoming long-term safety studies. Neurocrine, for its part, says it remains closely engaged with the FDA and stands by the drug's risk-benefit profile.
| What is true | What it is not |
|---|---|
| Seven deaths and 100+ serious adverse events were reported to the FDA AEMS system as of 31 July 2026, in patients who had taken Vykat XR. | Not proof Vykat caused them. Reported-after is not caused-by. No deaths occurred in the pivotal trial; the trial did show edema, then classed as low severity. |
| Three patient organizations (PWSA|USA, FPWR, IPWSO) issued a joint statement, with seven named PWS clinicians, calling for more careful patient selection and monitoring. | Not a call to stop prescribing. The groups explicitly stopped short of recommending against use. |
| Statement flags six risk factors for closer study: severe obesity, cardiac disease, pre-existing edema, severe respiratory compromise, untreated sleep apnea, prior severe respiratory infections. | Not a contraindication list. These are factors deserving caution and extra assessment, not automatic disqualifiers. |
| The label already warned of fluid overload; edema appeared in trials and was dose-related. | Not new information smuggled out. The signal is the same signal, now in sicker, wider, real-world patients. |
| Separately: Aardvark's phase 3 HERO trial of ARD-101 was paused in February, fully held by FDA in May, and terminated in June 2026, after cardiac findings in a healthy-volunteer study. | Not related to Vykat. A different drug, a different company, a reminder that this indication is hard. |
WHY THIS PAGE EXISTS
The association said it best: with every new treatment comes a responsibility to keep learning.
When we wrote the drugs page, Vykat was a one-line entry. The line is longer now. A safety signal that changes how clinicians prescribe is record, and this handbook records. What we will not do: rank the deaths, guess causality, or tell you to switch anything. That is a conversation between your clinician and the current FDA communications.